Gilberto Schwartsmann was born on August 18, 1955, in the city of Passo Fundo in the State of Rio de Janeiro, to Simão Schwartsmann and Maria Safra Schwartsmann.
In 1981, he graduated in Medicine from the Federal University of Rio Grande do Sul (UFRS), and two years later, became a specialist in Clinical Oncology from the Royal Marsden Hospital’s (RM) Middlesex Hospital University in London, England, in 1983. He continued to pursue his medical education with a Ph.D. in Pharmacology and Anti-Cancer Drugs from the Royal Free Hospital, also in England’s capital, in 1988, followed by a postdoctoral degree from the European Organisation for Research and Treatment of Cancer (EORTC) in 1991. That same year, Dr. Schwartsmann obtained specialization course certificates from EORTC and the U.S. National Cancer Institute (NCI) in 1992.
The oncologist holds the title of Research Professor at Porto Alegre’s Hospital das Clínicas (HCPA) university hospital complex and at the Federal University of Rio Grande do Sul (UFRS) and is committed to developing anti-cancer drugs at both organizations. At HCPA, he teaches the subject of Basic Oncology at the undergraduate level as well as other courses at the institution’s postgraduate program. Furthermore, he is a Tenured Professor at UFRS’s Postgraduate Program in Pharmacology and Therapeutics.
Moreover, Dr. Schwartsmann amasses the position of Head of the Kaplan Oncology Institute of Rio Grande do Sul and chairs the South-American Office for Anticancer Drug Development (SOAD). Also, he has composed Rio Grande do Sul’s Childhood Cancer Institute, of which he is the Founding Member, since 1993.
As a scholar, he has published three books and has nearly 200 self-penned scientific papers and articles under his name comprising the PubMed database, in addition to 2,000 mentions in the ISI Citation Index. He further holds seven patents within the realm of new Oncology-related medications and diagnostic tests.
Additionally, Dr. Schwartsmann has mentored over 60 students with their final papers and/or doctorate theses in Oncology at the Federal University of Rio Grande do Sul.
Some of the acclaimed oncologist’s main awards and distinctions include the Carmem Prudente medal granted by the São Paulo Society of Clinical Oncology (SPOC) in 2004, Walter Guezzi tribute bestowed during the State of Rio Grande do Sul Coloproctology Conference, and the Destaque em Pesquisa (Merit in Research) honor awarded by the Brazilian Society of Clinical Oncology (SBOC) in 2001.
In addition, Dr. Schwartsmann contributes as an editorial staff member to numerous organizations, such as The Lancet Oncobiology, Recent Patents in Anti-Infective Agents, Session of Oncology, and the Journal of the Brazilian Medical Association (RAMB). He is also a Member of a host of Brazilian as well as international societies like the Academia Sul-Riograndense de Medicina (ASRM) (Rio Grande do Sul Academy of Medicine – ASRM); European Society of Medical Oncology; American Society of Clinical Oncology; Royal Academy of Medicine of Spain; Argentinian Society of Clinical Oncology (AAOC); and the Latin American and Caribbean Society of Medical Oncology (SLACOM), of which he is a Founding Member. Finally, the oncologist and academician is part of the board of directors of the Iberê Camargo Foundation and serves as Vice-President of the 10th Mercosur Biennial.
Dr. Schwartsmann further holds the title of Medical Director and Founding Member of the Kaplan Oncology Institute and has the privilege of being the first Latin American to head the New Drug Development Office at the European Organisation for Research and Treatment of Cancer (EORTC). Additional accolades and positions include being a faculty member of the European Society for Medical Oncology, receiving an Honorary Doctorate by the Universidad Del Salvador (USAL) in Buenos Aires, Argentina, and serving as a clinician at the Ernesto Dornelles Hospital Cancer Center in Porto Alegre. For his outstanding contributions to medicine, the oncologist has been honored with the title of Honorary Citizen of the cities of Porto Alegre, Canoas, and Barra do Ribeiro, all of them in the State of Rio Grande do Sul.
On March 25, 2014, the board of the Fundação Médica do Rio Grande do Sul (State of Rio Grande do Sul Medical Foundation – Fundmed), a body tasked with representing faculty members of the Porto Alegre Hospital das Clínicas university hospital complex, the Medical School, and the Federal University of Rio Grande do Sul (UFRGS) held an event celebrating the Professor Gilberto Schwartsmann-led initiative of setting up scholarships.
Upon applying for a Full Member seat at the Academia Nacional de Medicina (National Academy of Medicine – ANM), Dr. Gilberto Schwartsmann submitted a dissertation titled “Experience with the Use of Thalidomide in Patients with Multiple Myeloma and Advanced Refractory Solid Tumors.”
Academic number: 614
Chair: 15
Member: Holder
Section: Medicine
Election: 02/05/2002
Inauguration: 04/06/2002
President: Augusto Paulino Soares de Souza Netto
Academic number: 614
Chair: 15
Member: Holder
Section: Medicine
Election: 02/05/2002
Inauguration: 04/06/2002
President: Augusto Paulino Soares de Souza Netto
Gilberto Schwartsmann was born on August 18, 1955, in the city of Passo Fundo in the State of Rio de Janeiro, to Simão Schwartsmann and Maria Safra Schwartsmann.
In 1981, he graduated in Medicine from the Federal University of Rio Grande do Sul (UFRS), and two years later, became a specialist in Clinical Oncology from the Royal Marsden Hospital’s (RM) Middlesex Hospital University in London, England, in 1983. He continued to pursue his medical education with a Ph.D. in Pharmacology and Anti-Cancer Drugs from the Royal Free Hospital, also in England’s capital, in 1988, followed by a postdoctoral degree from the European Organisation for Research and Treatment of Cancer (EORTC) in 1991. That same year, Dr. Schwartsmann obtained specialization course certificates from EORTC and the U.S. National Cancer Institute (NCI) in 1992.
The oncologist holds the title of Research Professor at Porto Alegre’s Hospital das Clínicas (HCPA) university hospital complex and at the Federal University of Rio Grande do Sul (UFRS) and is committed to developing anti-cancer drugs at both organizations. At HCPA, he teaches the subject of Basic Oncology at the undergraduate level as well as other courses at the institution’s postgraduate program. Furthermore, he is a Tenured Professor at UFRS’s Postgraduate Program in Pharmacology and Therapeutics.
Moreover, Dr. Schwartsmann amasses the position of Head of the Kaplan Oncology Institute of Rio Grande do Sul and chairs the South-American Office for Anticancer Drug Development (SOAD). Also, he has composed Rio Grande do Sul’s Childhood Cancer Institute, of which he is the Founding Member, since 1993.
As a scholar, he has published three books and has nearly 200 self-penned scientific papers and articles under his name comprising the PubMed database, in addition to 2,000 mentions in the ISI Citation Index. He further holds seven patents within the realm of new Oncology-related medications and diagnostic tests.
Additionally, Dr. Schwartsmann has mentored over 60 students with their final papers and/or doctorate theses in Oncology at the Federal University of Rio Grande do Sul.
Some of the acclaimed oncologist’s main awards and distinctions include the Carmem Prudente medal granted by the São Paulo Society of Clinical Oncology (SPOC) in 2004, Walter Guezzi tribute bestowed during the State of Rio Grande do Sul Coloproctology Conference, and the Destaque em Pesquisa (Merit in Research) honor awarded by the Brazilian Society of Clinical Oncology (SBOC) in 2001.
In addition, Dr. Schwartsmann contributes as an editorial staff member to numerous organizations, such as The Lancet Oncobiology, Recent Patents in Anti-Infective Agents, Session of Oncology, and the Journal of the Brazilian Medical Association (RAMB). He is also a Member of a host of Brazilian as well as international societies like the Academia Sul-Riograndense de Medicina (ASRM) (Rio Grande do Sul Academy of Medicine – ASRM); European Society of Medical Oncology; American Society of Clinical Oncology; Royal Academy of Medicine of Spain; Argentinian Society of Clinical Oncology (AAOC); and the Latin American and Caribbean Society of Medical Oncology (SLACOM), of which he is a Founding Member. Finally, the oncologist and academician is part of the board of directors of the Iberê Camargo Foundation and serves as Vice-President of the 10th Mercosur Biennial.
Dr. Schwartsmann further holds the title of Medical Director and Founding Member of the Kaplan Oncology Institute and has the privilege of being the first Latin American to head the New Drug Development Office at the European Organisation for Research and Treatment of Cancer (EORTC). Additional accolades and positions include being a faculty member of the European Society for Medical Oncology, receiving an Honorary Doctorate by the Universidad Del Salvador (USAL) in Buenos Aires, Argentina, and serving as a clinician at the Ernesto Dornelles Hospital Cancer Center in Porto Alegre. For his outstanding contributions to medicine, the oncologist has been honored with the title of Honorary Citizen of the cities of Porto Alegre, Canoas, and Barra do Ribeiro, all of them in the State of Rio Grande do Sul.
On March 25, 2014, the board of the Fundação Médica do Rio Grande do Sul (State of Rio Grande do Sul Medical Foundation – Fundmed), a body tasked with representing faculty members of the Porto Alegre Hospital das Clínicas university hospital complex, the Medical School, and the Federal University of Rio Grande do Sul (UFRGS) held an event celebrating the Professor Gilberto Schwartsmann-led initiative of setting up scholarships.
Upon applying for a Full Member seat at the Academia Nacional de Medicina (National Academy of Medicine – ANM), Dr. Gilberto Schwartsmann submitted a dissertation titled “Experience with the Use of Thalidomide in Patients with Multiple Myeloma and Advanced Refractory Solid Tumors.”